No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs

International Journal of Obesity

Volumn 31, Issue 6, 2007, Pages 1014-1022

  Cope, M B ^a   Jumbo Lucioni, P ^a   Walton, R G ^a   Kesterson, R A ^a,b   Allison, D B ^a   Nagy, T R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Energy intake; High fat diet; Olanzapine; Quetiapine; Risperidone; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; LIPID; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FAT INTAKE; FEMALE; FOOD INTAKE; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; LIPID DIET; LOW FAT DIET; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY COMPOSITION; BONE DENSITY; DIBENZOTHIAZEPINES; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; EATING; ENERGY INTAKE; FEMALE; LIPIDS; MICE; MICE, INBRED C57BL; RISPERIDONE; WEIGHT GAIN;

MUS; STEATOMYS PRATENSIS;

EID: 34249710871     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803533     Document Type: Article

References (66)

1. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-2967.
2. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev 2005; 6: 5-7.
3. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55: 277-284.
4. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83-96.
5. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215-220.
6. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101: 277-288.
7. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
8. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003; 48: 689-694.
9. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-281.
10. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 27-35.
11. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
12. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003; 10: 348-355.
13. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62: 7-10.
14. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19-28.
15. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry 2000; 2: 20-23.
16. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22-31.
17. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62: 32-37.
18. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51-57.
19. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-28.
20. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1-93.
21. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Portilla MP, Fernandez I et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003; 62: 77-88.
22. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
23. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
24. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374.
25. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749.
26. Bouchard RH, Demers MF, Simoneau I, Almeras N, Villeneuve J, Mottard JP et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 2001; 21: 110-111.
27. Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129-133.
28. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002; 3: 1773-1781.
29. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62: 347-349.
30. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol 1992; 262: R1025-R1032.
31. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, Surwit RS. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 2004; 53: 454-457.
32. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53: S215-S219.
33. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB. Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes Relat Metab Disord 2005; 29: 607-614.
34. Nagy TR, Clair AL. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 2000; 8: 392-398.
35. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159: 1055-1057.
36. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463-472.
37. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 2005; 182: 220-231.
38. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, Beaulieu S et al. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1305-1311.
39. Baptista T. Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry 2002; 63: 245-246.
40. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5: 279-299.
41. Ravussin E. Low resting metabolic rate as a risk factor for weight gain: role of the sympathetic nervous system. Int J Obes Relat Metab Disord 1995; 19: S8-S9.
42. Buscemi S, Verga S, Caimi G, Cerasola G. Low relative resting metabolic rate and body weight gain in adult Caucasian Italians. Int J Obes (Lond) 2005; 29: 287-291.
43. Trayhurn P. Thermoregulation in the diabetic-obese (db/db) mouse. The role of non-shivering thermogenesis in energy balance. Pflugers Arch 1979; 380: 227-232.
44. Trayhurn P, James WP. Thermoregulation and non-shivering thermogenesis in the genetically obese (ob/ob) mouse. Pflugers Arch 1978; 373: 189-193.
45. Blass DM, Chuen M. Olanzapine-associated hypothermia. Psychosomatics 2004; 45: 135-139.
46. Brevik A, Farver D. Atypical antipsychotic induced mild hypothermia. S D J Med 2003; 56: 67-70.
47. Hagg S, Mjorndal T, Lindqvist L. Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. J Clin Psychopharmacol 2001; 21: 113-115.
48. Parris C, Mack JM, Cochiolo JA, Steinmann AF, Tietjen J. Hypothermia in 2 patients treated with atypical antipsychotic medication. J Clin Psychiatry 2001; 62: 61-63.
49. Phan TG, Yu RY, Hersch MI. Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome. Med J Aust 1998; 169: 230-231.
50. Razaq M, Samma M. A case of risperidone-induced hypothermia. Am J Ther 2004; 11: 229-230.
51. Sharpe JK, Hills AP, Byrne NM, Stedman TJ. Resting metabolic rate in people taking atypical antipsychotic medication. Asia Pac J Clin Nutr 2004; 13: S157.
52. Arjona AA, Zhang SX, Adamson B, Wurtman RJ. An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152: 121-127.
53. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719-1722.
54. Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118-123.
55. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74: 1999-2008.
56. Fell MJ, Marshall KM, Williams J, Neill JC. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 2004; 18: 149-155.
57. Minet-Ringuet J, Even PC, Guesdon B, Tome D, de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 2005; 163: 204-211.
58. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-871.
59. Lewis DS, Bertrand HA, Masoro EJ, McGill Jr HC, Carey KD, McMahan CA. Preweaning nutrition and fat development in baboons. J Nutr 1983; 113: 2253-2259.
60. Spencer SA, Vinter J, Hull D. The effect in newborn rabbits of overfeeding on fat deposition, gross energetic efficiency, and metabolic rate. Pediatr Res 1985; 19: 127-130.
61. McCracken KJ, McNiven MA. Effects of overfeeding by gastric intubation on body composition of adult female rats and on heat production during feeding and fasting. Br J Nutr 1983; 49: 193-202.
62. Applegate EA, Upton DE, Stern JS. Exercise and detraining: effect on food intake, adiposity and lipogenesis in Osborne-Mendel rats made obese by a high fat diet. J Nutr 1984; 114: 447-459.
63. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006; 186: 561-571.
64. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
65. Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004; 65: 557-564.
66. Moghadasian MH, Frohlich JJ, McManus BM. Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 2001; 81: 1173-1183.